GABRP as a Radioligand Therapy Target
GABRP, gamma-aminobutyric acid type A receptor subunit pi, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, GABRP staining is highest in prostate cancer (100% of samples positive), skin cancer (100% of samples positive) and liver cancer (100% of samples positive). Evidence on whether GABRP internalizes is mixed. Clinical status: Clinical-stage (up to phase 3, any modality).
Is GABRP a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in prostate cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
GABRP expression in cancer
Protein expression of GABRP across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Prostate Cancer | 0.94 | High | 100% |
| Skin Cancer | 0.86 | High | 100% |
| Liver Cancer | 0.73 | High | 100% |
| Gastric Cancer | 0.70 | High | 100% |
| Ovarian Cancer | 0.70 | High | 100% |
| Endometrial Cancer | 0.69 | High | 100% |
| Colorectal Cancer | 0.67 | High | 100% |
| Head and Neck Cancer | 0.67 | High | 100% |
| Breast Cancer | 0.67 | High | 100% |
| Thyroid Cancer | 0.67 | High | 100% |
| Pancreatic Cancer | 0.67 | High | 100% |
| Melanoma | 0.64 | High | 100% |
| Kidney Cancer | 0.64 | High | 100% |
| Cervical Cancer | 0.61 | High | 92% |
| Neuroendocrine Tumors | 0.58 | High | 100% |
| Lung Cancer | 0.58 | High | 100% |
| Glioma | 0.56 | High | 100% |
| Bladder Cancer | 0.52 | High | 82% |
| Testicular Cancer | 0.41 | Medium | 78% |
| Lymphoma | 0.39 | Medium | 75% |
Is GABRP internalized?
Uncertain. Insufficient literature found.
GABRP clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for GABRP yet. Search ClinicalTrials.gov for GABRP trials.
GABRP normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See GABRP in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
GABRP gene essentiality (DepMap)
CRISPR knockout effect across 1244 cancer cell lines: 0.03 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related prostate cancer radioligand targets
PSMA (FOLH1) · HER3 (ERBB3) · c-MET (MET) · EGFR · EPCAM · FAP · B7-H3 (CD276) · STEAP2
See all radioligand therapy targets in prostate cancer.
See how GABRP ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.